We are incredibly proud our fearless leader, Dr. Prof. Bobby Gaspar, has been named to the inaugural 2024 #TIME100HEALTH list. Please read our press release for more information: bit.ly/4bnhEWs, and see the full list of honorees here: time.com/time100health.

Today we outlined our U.S. launch plans for Lenmeldy™ (atidarsagene autotemcel), the only approved therapy for eligible children with early-onset metachromatic leukodystrophy. Read more: bit.ly/4940qMp

We are thrilled to announce that the U.S. FDA has approved Lenmeldy™ (atidarsagene autotemcel), the only therapy for eligible children with early-onset metachromatic leukodystrophy in the U.S. Read more in our press release: bit.ly/4ceTmzr.

On #RareDiseaseDay please join us in helping raise awareness and #ShowYourColours in support of the millions of people living with rare diseases. Learn more at rarediseaseday.org

We look forward to participating in WORLDSymposia 2024 and hosting a symposia featuring expert speakers sharing their knowledge and experience to establish new standards and advance #newbornscreening through interdisciplinary collaboration. Learn more: bit.ly/3Ume5uB

We are pleased to share that Kyowa Kirin has successfully completed the previously announced acquisition of Orchard Therapeutics. Learn more: bit.ly/3Hydjmq

Earlier this month, we hosted the 4th MLD NBS Alliance Summit in Vienna which brought together experts and advocates with deep experience across the diagnostic journey and care continuum to advance our efforts to ensure widespread newborn screening for this devastating disease.

Today is World Sanfilippo Awareness Day. Join us in spreading awareness about this rare and life-limiting neurometabolic disease. Visit Cure Sanfilippo Fdn for more information: bit.ly/3UIcrAy #WorldSanfilippoDay

We look forward to joining NORD at this week’s #NORDSummit where our Chief Medical Officer Leslie Meltzer, Ph.D., will participate in a panel on opportunities in cell and gene therapy. Learn more: nordsummit.org.

We are excited to announce that Kyowa Kirin and Orchard Therapeutics announced that our companies have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics. Read more: bit.ly/45kK1RU

Today, we announced the acceptance of our Biologics License Application for OTL-200 in MLD under Priority Review. Read more: bit.ly/3rkvMyA

On #PRIDEday , we recognize inclusion and allyship are not confined to one day, week or month. At Orchard, we believe diversity is a key to our strength and vibrancy.

Tomorrow is International Neonatal Screening Day. We stand with the International Society of Neonatal Screening and like-minded organizations dedicated to advancing #NewbornScreening for genetic diseases. Learn more: neonatalscreeningday.org

Our team looks forward to participating in #epns2023 ! Click here for more information: epns-congress.com

Solidarity and allyship are key themes throughout the month of June and this #Juneteenth we are continuing the dialogue on diversity, equity and inclusion and encouraging all those in our Orchard to support causes dedicated to uplifting the Black community.

Orchard is excited to join the leukodystrophy community in taking strides to support Association ELA ‘Met tes baskets’ (wear your trainers) at work international challenge! Good luck to all involved! Learn more: bit.ly/3JeX8f4

Throughout #PRIDE month, and every day, we encourage our team to live our core values and always bring their authentic selves to our Orchard.

Earlier this week on #MPSAwarenessDay , we were honored to welcome Willow and her mother, Charlotte, to our global headquarters to hear their story of hope and resilience living with MPS-IH.

Today is #MPSAwarenessDay . Learn about this group of rare, life-limiting, inherited genetic diseases below and visit @MPSSocietyfor more information.

Our Chief Technical Officer Nicoletta Loggia, Ph.D. spoke at the Reuters Events Pharma #REpharmaUSA on the topic of innovation in cell and gene therapy manufacturing. Learn more: bit.ly/3nA8NNq